Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE BESANCON · Nov 14, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating the risks associated with medications called oral anticoagulants, which are used to prevent blood clots. The study aims to understand how often patients experience problems, known as adverse drug events, while being treated with these medications in the emergency department. These events can include serious bleeding from injuries, unexpected bleeding without injury, or even blood clots forming despite treatment. The goal is to gather information about the types of patients who may face these risks and to explore factors that could lead to these adverse events.

To be eligible for the study, participants must be at least 18 years old and currently receiving one of the specified oral anticoagulant medications. They should be admitted to the emergency department of Besançon University Hospital during the study period from January 1, 2018, to December 31, 2019. Participants can expect to have their health monitored, and researchers will analyze data over three years to better understand how these medications affect patient safety. This important research aims to improve care for patients on anticoagulants and reduce risks associated with their use.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Admission to adult emergency department of Besançon University Hospital
• • Study period: January 1, 2018 to December 31, 2019
• * Current oral anticoagulation therapy with:
• • Acenocoumarol
• • Apixaban
• • Dabigatran
• • Fluindione
• • Rivaroxaban
• • Warfarin
• Exclusion Criterion:
• • - Discontinuation of anticoagulant therapy for more than 24 hours